CHA2DS2-VASc score predict no-reflow phenomenon in primary percutaneous coronary intervention

被引:26
|
作者
Mirbolouk, Fardin [1 ]
Gholipour, Mahboobeh [1 ]
Salari, Arsalan [1 ]
Shakiba, Maryam [2 ]
Kheyrkhah, Jalal [1 ]
Nikseresht, Vahid [3 ]
Sotoudeh, Nozar [4 ]
Moghadam, Negar [4 ]
Mirbolouk, Mohammad Jaafar [4 ]
Far, Mani Moayeri [4 ]
机构
[1] Guilan Univ Med Sci, Sch Med, Heshmat Hosp, Cardiovasc Dis Res Ctr,Dept Cardiol, Rasht, Iran
[2] Guilan Univ Med Sci, Cardiovasc Dis Res Ctr, Rasht, Iran
[3] Guilan Univ Med Sci, Hlth Heart Res Ctr, Rasht, Iran
[4] Guilan Univ Med Sci, Dept Cardiol, Cardiovasc Dis Res Ctr, Rasht, Iran
关键词
CHA2DS2-VASc Score; STEMI; Primary PCI; No-reflow;
D O I
10.15171/jcvtr.2018.08
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: No-reflow is one of the major complications of primary percutaneous coronary intervention (PCI) in patients with acute ST elevation myocardial infarction. This phenomenon is associated with adverse outcomes in these patients. In the current study, we evaluated the effectiveness of CHA2DS2-VASc score in predicting no-reflow phenomenon. CHA2DS2-VASc score is a risk stratification method to estimate the risk of thromboembolism in patients with atrial fibrillation. Methods: In total, 396 patients with ST elevation myocardial infarction who had undergone primary PCI were evaluated in our study. Based on post interventional TIMI flow rate results, the patients were divided into two groups: control group (294 patients) and no-reflow group (102 patients). The CHA2DS2-VASc score was calculated for each participant. Multivariate regression analysis was performed to determine the predictive value of this score. Results: Our findings showed that CHA2DS2-VASc score can predict no-reflow independently (odds ratio [OR]: 3.06, 95% CI: 2.23-4.21, P < 0.001). Moreover, lower systolic blood pressure, higher diastolic blood pressure, grade 0 initial TIMI flow rate and smaller stent size were other independent predictors of the no-reflow in our study. We also defined a cut off value of >= 2 for the CHA2DS2-VASc score in predicting the no-reflow with a sensitivity of 88% and specificity of 67%, area under curve: 0.83 with 95% CI (0.79-0.88). Conclusion: The CHA2DS2-VASc score could be used as a simple applicable tool in the prediction of no-reflow before primary PCI in the acute ST elevation myocardial infarction patients.
引用
收藏
页码:46 / 52
页数:7
相关论文
共 50 条
  • [31] Prognostic value of GRACE and CHA2DS2-VASc score among patients with atrial fibrillation undergoing percutaneous coronary intervention
    Guo, Tingting
    Xi, Ziwei
    Qiu, Hong
    Wang, Yong
    Zheng, Jianfeng
    Dou, Kefei
    Xu, Bo
    Qiao, Shubin
    Yang, Weixian
    Gao, Runlin
    ANNALS OF MEDICINE, 2021, 53 (01) : 2215 - 2224
  • [32] CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients
    Gunduz, Ramazan
    Yildiz, Bekir Serhat
    Ozdemir, Ibrahim Halil
    Cetin, Nurullah
    Ozen, Mehmet Burak
    Bakir, Eren Ozan
    Ozgur, Su
    Bayturan, Ozgur
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2021, 52 (03) : 914 - 924
  • [33] CHA2DS2 VASc score and brachial artery flow-mediated dilation as predictors for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Rashed, Mohamed Ismail
    Saleh, Mohamed Ayman
    Elfekky, Ehab Mohamed
    Elmahmoudy, Ahmed Mohamed
    EGYPTIAN HEART JOURNAL, 2022, 74 (01):
  • [34] CHA2DS2 VASc score and brachial artery flow-mediated dilation as predictors for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Mohamed Ismail Rashed
    Mohamed Ayman Saleh
    Ehab Mohamed Elfekky
    Ahmed Mohamed Elmahmoudy
    The Egyptian Heart Journal, 74
  • [35] New R2-CHA2DS2-VASc score predicts no-reflow phenomenon and long-term prognosis in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention
    Zhang, Qinyao
    Hu, Meirong
    Ma, Shumei
    Niu, Tiesheng
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [36] CHA2DS2-VASc score as a novel predictor for contrast-induced nephropathy after percutaneous coronary intervention in acute coronary syndrome
    Chaudhary, Abhay Kumar
    Pathak, Vijay
    Kunal, Shekhar
    Shukla, Shubhra
    Pathak, Pooja
    INDIAN HEART JOURNAL, 2019, 71 (04) : 303 - 308
  • [37] CHA2DS2-VASc score as a predictor for contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention
    Elkholy, M. O. N. Hamdy
    Shehata, H.
    Abu Arab, T.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2150 - 2150
  • [38] Predictive Value of CHA2DS2-VASC Score for Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Acute Coronary Syndrome
    Kurtul, Alparslan
    Yarlioglues, Mikail
    Duran, Mustafa
    AMERICAN JOURNAL OF CARDIOLOGY, 2017, 119 (06): : 819 - 825
  • [39] Does CHA2DS2-VASc score predict mortality in chronic kidney disease?
    Goudis, Christos
    Daios, Stylianos
    Korantzopoulos, Panagiotis
    Liu, Tong
    INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (07) : 1737 - 1742
  • [40] The Use of Cha2ds2-vasc Score to Predict Functional Outcomes of Mechanical Thrombectomy
    Livesay, James
    Fogelson, Benjamin
    Stevens, Shawna
    Patel, Chirag
    Tahir, Hassan
    Dieter, William
    Wiseman, Brian
    Baljepally, Raj
    CIRCULATION, 2022, 146